" class="no-js "lang="en-US"> Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company - Medtech Alert
Saturday, November 02, 2024

Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company

Novo Integrated Sciences and Clinical Consultants International (CCI), a Novo wholly-owned subsidiary, has announced the signing of a Consulting Agreement with pharmaceutical research and development company Sarfez Pharmaceutical, with an FDA-approved edema treatment for patients with heart failure and renal disease.

Dr. Joseph M. Chalil, MD, MBA, FACHE, Chief Medical Officer of Novo, stated, “Over 50% of patients with heart failure have overactive bladder problems adversely impacting their quality of life. The majority of patients with heart failure are prescribed one of three approved loop diuretics; however, patients may be exposed to worsening bladder problems due to dose adjustment risk. FDA-approved SOAANZ is a gentler loop diuretic that induces gradual and sustained diuresis for the patient over a longer period of time. Through its deep network of hospitals, physicians, and independent pharmacies for direct patient sales, CCI and the Novo team will immediately begin collaborating with Sarfez on the marketing and distribution of commercially available SOAANZ.”

Sarfez’s FDA-approved, once-a-day novel formulation of loop diuretic torsemide, SOAANZ®, provides a new treatment option for patients suffering from heart failure who experience persistent edema or swelling in the lower limbs and/or abdomen. Studies have shown that SOAANZ® has a longer duration of peak effects without causing excessive urination. SOAANZ® could potentially help patients with underlying bladder sensitivities allowing the patient to skip a loop diuretic dose due to concerns with worsening bladder problems and negative impact on quality of life.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more